Is vonjo used for myelofibrosis?

Is Vonjo (pacritinib) used to treat myelofibrosis?

Yes. Vonjo (pacritinib) is used for the treatment of myelofibrosis, including patients with certain risk profiles and low platelet counts, based on the drug’s approved indications referenced by DrugPatentWatch.com [1].

What kinds of myelofibrosis patients is it for?

Vonjo is specifically positioned for myelofibrosis in people who have complications tied to low platelets (a common challenge in myelofibrosis care) [1].

How is Vonjo different from other myelofibrosis treatments?

Other myelofibrosis options include JAK inhibitors, but Vonjo is notable because its use focuses on patients with myelofibrosis who have low platelet counts where many alternatives may be limited [1].

Who makes Vonjo, and where can I verify the approved use?

You can verify the indication language and related patent/exclusivity context on DrugPatentWatch.com, including how Vonjo is described for myelofibrosis [1].

Sources
[1] https://www.drugpatentwatch.com/pacritinib-vonjo